- Can see the results in a short time 30 min. - More convenient than using blood. - Rapid production and supply are possible. - Convenient for personal use or at home. - Sensitivity 95% - Certified For EUROP And USA - Min order Discussed, Quote First - Fast delivery all Around the world By DHL FEDEX - In stock Korea by OTG. * Can supply Blood type Rapid test kit avail
Feature: The configuration is complete. It's convenient to treat different parts of the pain Each type of this analgesia needle can be made according to clinical demands. There are different types of analgesia needle in the package. so It avoid cross infections. The needle tube with scale and vernier which convenient to the operation. It used dialysis paper medical packaging materials. Ensure the safety of medical staff and patients. Specification: Type OD(mm) Length(mm) Edge shape Color Code Remark Pain treatment needle:#7 0.7 90 Cant Black With scale and vernier Pain treatment needle:#9 0.9 90 Cant Yellow With scale and vernier
Our HCG Strips are a reliable and user-friendly solution for at-home pregnancy testing. These highly sensitive strips are designed to detect the presence of human chorionic gonadotropin (HCG) hormone in urine, a hormone produced during pregnancy. With their simple, dip-and-read design, these strips provide quick and accurate results within minutes. A clearly visible test and control line make interpretation effortless, even for first-time users. Our HCG Strips are manufactured with precision, ensuring consistent and dependable results. These strips offer privacy and convenience, empowering individuals to confirm pregnancy discreetly and with confidence in the comfort of their own homes.
Dengue Test
Ketone Reagent Test Strips for Urinalysis Contains Pack of 100 Test Strips in sealed retail box pack.
100 Strips To Screen Glucose And Protein Levels In Urine Packed In Airtight Bottle And Box Protection With Silica. Good Till Opened
Dengue Test
Ketone Reagent 10Parameter Urine Test Strips Specifications: Keep away from light and moisture Contains 100 test strips in sealed single pack. Immediately close cap and do not remove desiccants Do not touch areas of reagents strips while testing as well as during result Read instructions before use Please note : This product is For Ketone analysis only (Not for Glucose) Ketone Reagent Test Strips for Urinalysis â?? Contains Pack of 100 Test Strips in sealed retail box pack.
Medrop Hcg Test Cards And Dipsticks
Test Strip 50 for Blood Glucose Meter Accu-chek Active
Accu-Chek Performa 100 Test Strips (1 Box x 100 Each) Blood Glucose Test Strips
We are suppliers of BEST QUALITY One Touch Test Strip and looking for serious buyers in need of our products, contact with us for more details OneTouch Ultra Blue Diabetic Test Strips provide fast and less painful testing of glucose levels. Designed for use with the OneTouch Ultra Soft Automatic Blood Sampler and OneTouch UltraSoft Lancets, this blood test strip is ideal for diabetic patients who need to monitor their body glucose level at home.
OneTouch Ultra Blue Blood Glucose Test Strips, 50 Ct: Test Strips, Blue Proven accuracy For blood glucose testing with the OneTouch Ultra Family of Meters and the OneTouch Ping Meter Remote. DoubleSure technology automatically checks each sample twice to confirm their result Requires just a speck of blood 1 vial of 50 test strips
PC-PASS Protein Characterization Analysis Protein Characterization (Physicochemical property of proteins) structure analysis using mass spectrometry provides results that meet the requirements of the FDA, the MFDS and other regulatory authorities regarding novel therapies or biosimilars. Based on basic amino acid analysis (full sequencing), we perform post-translational modification (PTM) analysis, which is important for protein potency and stability. In this regard, we can perform test methods based on design of experiment (DOE) statistical methodology and deliver documents to be submitted to regulatory authorities. Protein identification and quantification : Structural analysis of all types of protein therapeutics, including monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and enzymes - Full Length-Amino acids sequencing Peptide identification of each peak through peptide mapping (MS spectrum confirmation, MS/MS spectral analysis with 100% AA matches) - Improved N- and C-terminal sequencing of proteins Post-translational modification (PTM) : More reliable results based on design of experiment (DOE) statistical methodology to perform the experiments systematically and analyze data efficiently - Disulfide bond analysis ID Total possible lankage analysis - Deamidation identification and quantification - Phosphorylation identification and quantification , phospho-proteomic analysis - Other functional modifications Glycomics : Single protein analysis and research of protein complexes with glycosylation closely related to biological function and toxicity as well as structural stability of proteins - Glycosylation site determination - Glycan profiling - Site-specific glycan identification and quantification - Glycomics research with glycan enrichment
Biomarker Diseases Diagnosis Blood Tests Proteomics-based early diagnosis Provides a quick and accurate solution for early diagnosis of major diseases by utilizing multiple proteomic biomarker-based blood tests. Advantages of proteomics-based early diagnosis: Proteomics-based early diagnosis determines the presence of disease by identifying proteins that are specifically expressed in diseases and using these as biomarkers to measure the quantitative values of the relevant proteins in blood. Proteomics analysis has been assessed as highly likely to be used as a universal primary screening method because analysis can be performed even with trace samples, such as a few drops of blood.
Proteomics-based Early diagnosis using multiple markers provides a quick and accurate solution for early diagnosis of major diseases by utilizing multiple proteomic biomarker-based blood tests. Early diagnostic solutions BERTIS has commercialized MASTOCHECK, the worlds first proteomics-based blood test solution for early diagnosis of breast cancer, and clinical trials are being conducted on biomarkers for various cancers. Ultimately, these technologies are being used to continually expand the pipeline to allow dozens of diseases to be diagnosed with a single blood test.
PASS is an analysis solution optimized for academia and pharma research. The proprietary solution was derived from proven technology and innovation embedded in Mastocheck, a proteomics-based early cancer diagnostics approved by Ministry of Food and Drug Safety (MFDS). Bertis developed the PASS solution based on its pan-omics, bioinformatics, and artificial intelligence (AI) technologies. We provide a variety of analyzes for proteomic analysis, biomarker discovery and verification, new drug development, clinical process development, etc. PASS is a platform for integrative analysis of pan-omics data, based on our proven and reliable bioinformatics analysis capabilities. Our team consists of experienced scientists with an extensive track record of research achievements spanning more than a decade in mass spectrometry-based proteomics. Bertis possesses the core expertise and proprietary technology for pan-omics (multi-omics) analysis to provide customized solutions in all fields where omics data analysis is applicable. With PASS, you can leverage Bertis scientific resources and cutting-edge tools to advance your research projects and goals, from the design stage to the interpretation and visualization of bioinformatics analysis results.
Exo-PASS Exosomes contain proteins, lipids, nucleic acids, and metabolites, and can be easily enriched from biofluids, providing very valuable information for early detection and monitoring of diseases. The Ministry of Food and Drug Safety requires RNA, lipid and proteomic analyses in its guidelines for the development of exosome therapeutics, and PASS provides these analyses in an all-in-one package. Exosome RNA Sequencing: PASS enables rapid and efficient isolation of RNAs and profiling of exosome nucleic acids using qRT-PCR and novel sequencing methods. Exosome Lipidomics: We perform high-reliability and high-sensitivity analysis through an ultra-high-performance tool (UPLC, Orbitrap Exploris 480 MS) and lipid analysis experts who have been producing and interpreting analysis data for many years. Exosome Proteomics: PASS offers and performs quantification analysis that meets customer needs based on the unique expertise in exosome protein extraction. We provide reliable results through deep profiling of exosome proteome and a specialized data library. Our world-class bioinformatics research team at Bertis reviews and interprets pan-omics data (RNA/Lipid) to support in-depth research.
Proteomics-based early diagnosis determines the presence of disease by identifying proteins that are specifically expressed in diseases and using these as biomarkers to measure the quantitative values of the relevant proteins in blood. Proteomics analysis has been assessed as highly likely to be used as a universal primary screening method because analysis can be performed even with trace samples, such as a few drops of blood. High diagnostic accuracy : Quantitative values of biomarkers are measured and entered in a unique algorithm with applied AI. Convenience : No burden of inconvenience caused due to the use of a separate diagnostic device other than blood sampling Efficiency: Provides diagnosis opportunities to more people in situations where personnel and devices are limited
MastoCheck is a blood test that can easily screen for breast cancer at an early stage. Breast cancer is diagnosed early by substituting the quantitative values of three types of protein biomarkers in the blood, which are closely related to breast cancer, into a unique, patented algorithm. An innovative and convenient test method that detects early breast cancer with an accuracy of 92% (based on the patent) by using only a very small amount of blood. Bertis has developed multiple markers that can detect early breast cancer with an accuracy of 92% through identification of multiple proteins that are expressed sensitively in early-stage breast cancer and combination of certain proteins that demonstrated high accuracy and reproducibility among these combinations. DEVELOPMENT PROCESS: - MASTOCHECK was developed by a team led by Professor Dong-Young Noh, a world-renowned authority on breast cancer, of Seoul National University. - After analyzing approximately 600,000 proteins and selecting 3 markers exhibiting optimal accuracy, the highest accuracy was obtained by adding Bertis�¢?? own algorithm that enhances accuracy. - After several years of repeated validation work, a medical device product license was obtained from the MFDS in January 2019. To date (as of September 2023), MASTOCHECK has been introduced to about 400 hospitals and screening institutions nationwide, with priority given to large screening institutions.
